Date: 2015-12-18
Type of information: Nomination
Compound:
Company: Ariad Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 18, 2015, Ariad Pharmaceuticals announced that its Board of Directors has voted unanimously to appoint Paris Panayiotopoulos President and Chief Executive Officer (CEO), effective January 1, 2016 . Panayiotopoulos joins Ariad from his current position of President of EMD Serono, Inc. Panayiotopoulos also has been elected to Ariad's Board of Directors. He will succeed Harvey J. Berger , M.D., Ariad's founder, chairman and CEO. Panayiotopoulos, 41, is a global biopharmaceutical leader. At EMD Serono and its parent company Merck KGaA, he achieved organizational turnarounds in the United States, Japan and Western Europe by building high-performing and trusting teams, and creating an enduring vision and strategy in each role that he served. Previously, Panayiotopoulos held global leadership roles focusing on strategic marketing, cross-functional portfolio management and restructuring. Prior to this, he was at Eli Lilly & Co. Panayiotopoulos holds a combined BSc in Chemistry and Management Studies from University College London and a MSc in Marketing and Product Management from Cranfield Business School in the UK .
Financial terms:
Latest news:
